1.91
전일 마감가:
$1.97
열려 있는:
$1.97
하루 거래량:
2.51M
Relative Volume:
0.89
시가총액:
$292.94M
수익:
-
순이익/손실:
$-56.85M
주가수익비율:
-1.2251
EPS:
-1.559
순현금흐름:
-
1주 성능:
-4.50%
1개월 성능:
-11.57%
6개월 성능:
+16.46%
1년 성능:
+5.52%
Fractyl Health Inc Stock (GUTS) Company Profile
명칭
Fractyl Health Inc
전화
781-902-8800
주소
3 VAN DE GRAAFF DRIVE, BURLINGTON
GUTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
GUTS
Fractyl Health Inc
|
1.91 | 302.14M | 0 | -56.85M | 0 | -1.559 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-28 | 개시 | Ladenburg Thalmann | Buy |
| 2024-02-28 | 개시 | Evercore ISI | Outperform |
| 2024-02-27 | 개시 | BofA Securities | Buy |
| 2024-02-27 | 개시 | Morgan Stanley | Overweight |
Fractyl Health Inc 주식(GUTS)의 최신 뉴스
Earnings Risk: What is the dividend yield of Fractyl Health IncTrade Signal Summary & Community Supported Trade Ideas - baoquankhu1.vn
Is Fractyl Health Inc undervalued by DCF analysis2025 Pullback Review & High Accuracy Swing Trade Signals - baoquankhu1.vn
MACD Signal: What is the earnings history of Fractyl Health IncJobs Report & Safe Entry Zone Identification - baoquankhu1.vn
Returns Recap: Is BNAI still a buy after recent gainsWeekly Trend Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Investment Review: Is Fractyl Health Inc in a long term uptrendJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Institutional shareholders may be less affected by Fractyl Health, Inc.'s (NASDAQ:GUTS) pullback last week after a year of 8.1% returns - simplywall.st
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why retail investors favor Fractyl Health Inc. stockJuly 2025 Selloffs & Daily Oversold Bounce Ideas - ulpravda.ru
Is Fractyl Health Inc. stock a contrarian buyJuly 2025 Closing Moves & Trade Opportunity Analysis - ulpravda.ru
Can Fractyl Health Inc. stock deliver surprise earnings beatJuly 2025 Snapshot & Low Drawdown Trading Techniques - Улправда
Fractyl Health, Inc.Common Stock (NQ: GUTS - FinancialContent
Fractyl Health outlines strategic outlook for 2026 - MSN
Fractyl Health: Advancing Revita and Rejuva Pipelines Toward 2026 Clinical and Regulatory Catalysts Supports Buy Rating - TipRanks
What margin trends mean for Fractyl Health Inc. stockLow Beta Stocks & Make Confident Moves With Forecasting Models - ulpravda.ru
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness - The Globe and Mail
Fractyl Health, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Fractyl Health appoints Lara Smith Weber as new CFO By Investing.com - Investing.com South Africa
Fractyl Health Appoints New Chief Financial Officer - TipRanks
Fractyl Health appoints Lara Smith Weber as new CFO - Investing.com India
Fractyl Health announces catalyst-rich clinical and funding outlook - MSN
Analysts keep buy ratings on Fractyl Health (GUTS) - MSN
Fractyl Health Announces Catalyst-Rich Clinical and Funding Outlook - TipRanks
Millions stopping GLP-1 drugs face what's next as firm tests new option - Stock Titan
Fractyl Health’s REVEAL-1 study shows positive six-month results for Revita in maintaining weight and glycemic control post-GLP-1 use - MSN
Analysts Keep Buy Ratings on Fractyl Health (GUTS) - Finviz
Fractyl Health’s REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use - Yahoo Finance
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Stop Loss: Why Fractyl Health Inc stock remains undervaluedWeekly Volume Report & Trade Opportunity Analysis - moha.gov.vn
Aug EndMonth: Why retail investors favor Fractyl Health Inc stock2025 Investor Takeaways & Low Volatility Stock Suggestions - moha.gov.vn
Entry Recap: Why Fractyl Health Inc stock remains resilientJuly 2025 Snapshot & AI Powered Market Entry Ideas - moha.gov.vn
GUTS SEC FilingsFractyl Health 10-K, 10-Q, 8-K Forms - Stock Titan
Is Fractyl Health Inc. stock in correction or buying zoneWeekly Market Report & Daily Stock Trend Watchlist - Улправда
Aug Technicals: Why Fractyl Health Inc stock remains undervaluedJuly 2025 Recap & Fast Moving Market Watchlists - moha.gov.vn
Canaccord Genuity reiterates Buy rating on Fractyl Health stock By Investing.com - Investing.com South Africa
Canaccord Genuity reiterates Buy rating on Fractyl Health stock - Investing.com
Why Fractyl Health Inc. stock remains resilient2025 Historical Comparison & Technical Entry and Exit Alerts - DonanımHaber
Fractyl Health Inc (GUTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fractyl Health Inc 주식 (GUTS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Royan Ajay | Director |
Mar 14 '25 |
Buy |
1.28 |
17,901 |
22,980 |
17,901 |
| Barnes Kelly Ann | Director |
Mar 14 '25 |
Buy |
1.30 |
31,000 |
40,210 |
31,000 |
| SCHULMAN AMY W | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| BRADLEY WILLIAM | Director |
Mar 13 '25 |
Buy |
1.26 |
16,129 |
20,358 |
16,129 |
| Conaway Samuel | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Option Exercise |
1.70 |
90,972 |
154,652 |
582,301 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Option Exercise |
1.70 |
20,948 |
35,612 |
512,277 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Sale |
1.82 |
90,972 |
165,205 |
491,329 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Sale |
1.95 |
20,948 |
40,798 |
491,329 |
| Caplan Jay David | President, Chief Product Off. |
Jan 31 '25 |
Option Exercise |
1.70 |
22,346 |
37,988 |
175,890 |
자본화:
|
볼륨(24시간):